leisure time -WSS

leisure time

author：Wikipedia 2025-10-02 23:47:29 - browse：55457

Astrazeneca office building -- health policy coverage from STAT — AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

focus

explore

WSS

American taxpayers paid $1.8 trillion in health care costs in 2022

Nonprofit, backed by Microsoft, to certify AI tools in health care

American taxpayers paid $1.8 trillion in health care costs in 2022

Does Paxlovid work in people vaccinated against Covid

Medicare Advantage coverage denials need scrutiny, senators say

Goldman Sachs launches $650M fund for life science investments

leisure time

leisure time

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Videos point to link between seizures and unexplained toddler deaths

Heart attack and stroke risk calculators need revising

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Peter Hotez and the public health issue of online harassment

Life science postdocs should get big pay hike, NIH panel says

Continuity nursing helped my family in our darkest PICU moments

Chronically ill young patients struggle to find fertility info

Jerome Adams on the need for new antivirals for Covid

A single drug, study failures leave Anavex with nothing but cash

leisure time

JPM pitch from hospitals? Revenue streams outside of patient care

J&J to buy cancer drug developer Ambrx Biopharma

A preacher's new calling: Diversifying neuroscience research

Feng Zhang CRISPR delivery startup lays off quarter of staff

Allen Institute goes after foundational questions, CEO Costa says

Allen Institute goes after foundational questions, CEO Costa says

knowledge

focus

explore

entertainment